University of Zurich (UZH), Switzerland - Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity [Medical Xpress, November 2021]

Title:

Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity

By:

University of Zurich

Published:

Medical Xpress, 22 November 2021

https://medicalxpress.com/news/2021-11-exposure-harmless-coronaviruses-boosts-sars-cov-.html

From the article:

The population's immunity to SARS-CoV-2, achieved either through infection or vaccination, is crucial to overcome the COVID-19 pandemic. A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity—previous antibody responses to other, harmless coronaviruses. "People who have had strong immune responses to other human coronaviruses also have some protection against SARS-CoV-2 infection," says Alexandra Trkola, head of the Institute of Medical Virology at UZH.

 

ALSO SEE

 

Irene A. Abela et al, Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity, Nature Communications (2021). DOI: 10.1038/s41467-021-27040-x 

Science, 28 October 2020 - Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Title:

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

 

Authors:

Ania Wajnberg, Fatima Amanat, Adolfo Firpo, Deena R. Altman, Mark J. Bailey, Mayce Mansour, Meagan McMahon, Philip Meade, Damodara Rao Mendu, Kimberly Muellers, Daniel Stadlbauer, Kimberly Stone, Shirin Strohmeier, Viviana Simon, Judith Aberg, David L. Reich, Florian Krammer & Carlos Cordon-Cardo

 

Published:  

Science, 28 October 2020

https://science.sciencemag.org/content/early/2020/10/27/science.abd7728?rss=1

Abstract:

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein, based on a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City. We also show that titers are relatively stable for at least a period approximating 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody responses. These titers remain relatively stable for several months after infection.

The Rosalind Franklin Institute, Oxford University, Diamond Light Source & Public Health England: Engineered Nanobodies – Derived From Llama Antibodies – Neutralize COVID-19 Virus

Title:
Engineered Nanobodies – Derived From Llama Antibodies – Neutralize COVID-19 Virus

By:
The Rosalind Franklin Institute

Published:
SciTecDaily, 14 July 2020
https://scitechdaily.com/engineered-nanobodies-derived-from-llama-antibodies-neutralize-covid-19-virus/

From the article:
Antibodies derived from llamas have been shown to neutralize the SARS-CoV-2 virus in lab tests, UK researchers announced today.
 
The team involves researchers from the Rosalind Franklin Institute, Oxford University, Diamond Light Source and Public Health England. They hope the antibodies – known as nanobodies due to their small size – could eventually be developed as a treatment for patients with severe COVID-19. The peer-reviewed findings are published in Nature Structural & Molecular Biology.

Video (ZDoggMD, 19 April 2020) titled How Fatal Is COVID? The Stanford Antibody Prevalence Study

Title of video:
How Fatal Is COVID? The Stanford Antibody Prevalence Study

Published:
ZDoggMD, 19 April 2020
Available: https://www.youtube.com/watch?v=T-KpR2NdSos&feature=youtu.be

Video is based on the following scholarly article:
COVID-19 Antibody Seroprevalence in Santa Clara County, California

Authors:
Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra-Walker, James Tedrow, Dona Tversky, Andrew Bogan, Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis & Jay Bhattacharya

Published:
medRxiv, 14 April 2020
https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v2
This article is a preprint and has not been certified by peer review.

From the abstract:
"Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in a community sample drawn from Santa Clara County. Methods On April 3-4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay."